SEOUL, July 13 (Reuters) - Round-up of South Korean financial markets:
South Korean shares jumped on Monday as an analysis of an antiviral drug to treat COVID-19 yielded positive results, while investors awaited corporate earnings and China's June trade data due this week. The Korean won and the benchmark bond gained.
The country's benchmark KOSPI closed up 35.81 points, or 1.67%, to 2,186.06, logging the sharpest daily gain in a month.
Market sentiment improved after U.S. biopharmaceutical company Gilead Sciences said an analysis showed its antiviral remdesivir helped reduce the risk of death in severely ill COVID-19 patients, but cautioned that rigorous clinical trials were needed to confirm the benefit.
Meanwhile, Korea Customs Service data showed that South Korean exports for the first 10 days of this month slid 1.7% from last year, but those to China and the United States rose 9.4% and 7.3%, respectively.
Foreigners were net buyers of 100.2 billion won ($83.48 million) worth of shares on the main board.
The won was quoted at 1,200.9 per dollar on the onshore settlement platform, 0.30% higher than its previous close at 1,204.5.
In offshore trading, the won was quoted at 1,200.2 per dollar, nearly unchanged from the previous day, while in non-deliverable forward trading its one-month contract was quoted at 1,200.1.
The trading volume during the session in the KOSPI index was 641.52 million shares. Of the total traded issues of 900, the number of advancing shares was 608.
In money and debt markets, September futures on three-year treasury bonds fell 0.04 points to 111.99.
The most liquid 3-year Korean treasury bond yield rose by 1.2 basis points to 0.863% in late afternoon trade, while the benchmark 10-year yield rose by 2.3 basis points to 1.420%.

Sumber : reuters.com